Advances in the prevention of graft-versus-host disease after hematopoietic cell transplantation.
A brief historic review of bone-marrow transplantation, human leukocyte antigen matching, pretransplant conditioning, and the use of peripheral blood stem cells in hematopoietic cell transplantation (HCT) is presented. Graft-versus-host disease (GVHD) is one of the primary challenges to successful HCT. GVHD, its clinical impact and traditional prophylactic therapies, as well as recent advances in GVHD prevention, are discussed.
Anasetti
Claudio
C
Blood and Marrow Transplant Program, H. Lee Moffitt Cancer Center and Research Institute, Division of Interdisciplinary Oncology, University of South Florida, Tampa, FL, USA. AnasetC@moffitt.usf.edu
D006086:Graft vs Host Disease / Q000209:etiology / Q000276:immunology / Q000517:prevention & control*; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D006648:Histocompatibility; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D019172:Transplantation Conditioning
D007166:Immunosuppressive Agents